The Multifaceted Future of Pharma
We asked over 100 industry professionals for their views on the future of the pharma and biopharma industries, including key disruptors and what can be improved… The key trends? AI, cell and gene therapies, and a need to reduce costs and improve patient access.
The Medicine Maker launched in September 2014 (Happy 10th Anniversary to us!). As part of celebration, we reached out to you – the medicine making community – to ask for your views on the last decade in pharma and healthcare, including key disruptors, and the big changes we can expect in next 10 years.
Overwhelmingly, well over 100 of you submitted your thoughts. And so, we decided to release The Medicine Maker’s Multifaceted Future of Pharma over the course of 11 exciting chapters. You can access a new chapter each month below.
Featuring viewpoints from Boehringer Ingelheim, Bruker BioSpin, the Swiss Biotech Association, and more. Key topics include AI, digitalization, sustainability initiatives, continued innovation in cell and gene therapies, and a growing focus on accessibility versus pricing.
Coming in mid-October, Chapter 2 will focus on research innovation and drug discovery.
